Response to the BRAF/MEK inhibitors dabrafenib/trametinib in an adolescent with a BRAF V600E mutated anaplastic ganglioglioma intolerant to vemurafenib

Efficacy of BRAF V600E targeted therapies in brain tumors harboring the mutation has been shown in several case reports and is currently being studied in larger clinical trials. Monotherapy with vemurafenib has been associated with significant side effects, including rashes, papillomas, and squamous...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Pediatric blood & cancer 2018-05, Vol.65 (5), p.e26969-n/a
Hauptverfasser:	Marks, Asher M., Bindra, Ranjit S., DiLuna, Michael L., Huttner, Anita, Jairam, Vikram, Kahle, Kristopher T., Kieran, Mark W.
Format:	Artikel
Sprache:	eng
Schlagworte:	Adolescent Antineoplastic Combined Chemotherapy Protocols - therapeutic use AYA BRAF inhibitor BRAF V600E Brain Neoplasms - drug therapy Brain Neoplasms - genetics Brain Neoplasms - pathology Brain tumors Case reports Clinical trials CNS tumor Drug Resistance, Neoplasm - drug effects Female ganglioglioma Ganglioglioma - drug therapy Ganglioglioma - genetics Ganglioglioma - pathology Hematology Humans Imidazoles - administration & dosage MAP Kinase Kinase 1 - antagonists & inhibitors MEK inhibitor MEK inhibitors Mutation Oncology Oximes - administration & dosage Pediatrics Prognosis Proto-Oncogene Proteins B-raf - antagonists & inhibitors Proto-Oncogene Proteins B-raf - genetics Pyridones - administration & dosage Pyrimidinones - administration & dosage Side effects Skin Squamous cell carcinoma Targeted cancer therapy Vemurafenib - administration & dosage
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Beschreibung
Zusammenfassung:	Efficacy of BRAF V600E targeted therapies in brain tumors harboring the mutation has been shown in several case reports and is currently being studied in larger clinical trials. Monotherapy with vemurafenib has been associated with significant side effects, including rashes, papillomas, and squamous cell carcinomas. Here we describe an adolescent female with anaplastic ganglioglioma and significant skin reaction to vemurafenib with subsequent tumor response and tolerance to the BRAF/MEK inhibitor combination of dabrafenib and trametinib without recurrence of previous reaction.
ISSN:	1545-5009 1545-5017
DOI:	10.1002/pbc.26969